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Although DNAmethylation is commonly invoked as a
mechanism for transcriptional repression, the extent
to which it actively silences transcription factor (TF)
occupancy sites in vivo is unknown. To study the
role of DNA methylation in the active modulation of
TF binding, we quantified the effect of DNA methyl-
ation depletion on the genomic occupancy patterns
of CTCF, an abundant TF with known methylation
sensitivity that is capable of autonomous binding to
its target sites in chromatin. Here, we show that the
vastmajority (>98.5%) of the tens of thousands of un-
occupied, methylated CTCF recognition sequences
remain unbound upon abrogation of DNA methyl-
ation. The small fraction of sites that show methyl-
ation-dependent binding in vivo are in turn character-
ized by highly variable CTCF occupancy across cell
types. Our results suggest that DNA methylation is
not a primary groundskeeper of genomic TF land-
scapes, but rather a specialized mechanism for sta-
bilizing intrinsically labile sites.
INTRODUCTION
DNA methylation is required for mammalian development and
plays a central role in imprinting (Jones, 2012; Li et al., 1992).
Cytosine methylation in the context of CpG dinucleotides has
been widely invoked as a causal mechanism for transcriptional
repression at promoter regions, and a correlation between
DNAmethylation and gene expression has long been recognized
(Jones and Taylor, 1980). Recent findings indicate that dynamic
demethylation during development is largely restricted to pro-
moter-distal regulatory elements marked by DNase I-hypersen-
sitive sites (DHSs) (Hon et al., 2013). However, themechanism by
which DNA methylation perturbs chromatin state and regulatory
elements in a site-specific fashion remains obscure (Deaton and
Bird, 2011). Various possibilities have been suggested including
direct potentiation of repressive chromatin features (Collings1184 Cell Reports 12, 1184–1195, August 18, 2015 ª2015 The Authoet al., 2013; Ramirez-Carrozzi et al., 2009), recruitment of meth-
ylcytosine-specific repressive factors (Baubec et al., 2013; Lewis
et al., 1992; Tate and Bird, 1993), and physical obstruction of the
transcription factor (TF) DNA interface (Hu et al., 2013; Tate and
Bird, 1993). Consistent with the latter hypothesis, DNA methyl-
ation is specifically depleted at occupied TF-binding sites in vivo
(Groudine and Conkin, 1985; Lister et al., 2009; Neph et al.,
2012b; Thurman et al., 2012). Although DNA methylation is
widely assumed to inhibit TF occupancy in vivo, mechanistic
studies suggest that methylation of TF recognition sites may
follow TF evacuation (Brandeis et al., 1994; Feldmann et al.,
2013; Lienert et al., 2011; Lin et al., 2000; Macleod et al., 1994;
Matsuo et al., 1998; Stadler et al., 2011; Thurman et al., 2012).
It thus remains unclear whether altered methylation patterns
themselves invoke transcriptional repression or are instead
downstream consequences of other regulatory factors.
Here we investigate the causal relationship between genome-
wide DNA methylation and TF occupancy using the model TF
CCCTC-binding factor (zinc finger protein) (CTCF), an abundant
TF with known methylation sensitivity that is capable of autono-
mous binding to its target sites in chromatin (Phillips and Corces,
2009). CTCF occupancy is tightly anticorrelated with DNA
methylation at its binding sites in vivo (Phillips and Corces,
2009; Wang et al., 2012), and its binding to DNA is abrogated
by methylation in vitro (Bell and Felsenfeld, 2000; Filippova
et al., 2001; Hark et al., 2000; Renda et al., 2007). Using a
combination of genetic and chemical DNAmethylation depletion
experiments coupled to genome-wide occupancy analysis, we
found that the CTCF-binding landscape remains largely un-
changed in response to removal of DNA methylation. However,
we observed a small minority of sites that reproducibly exhibited
methylation-dependent occupancy. These sites were distin-
guished by high CpG content, the presence of specific CTCF
recognition sequences that incorporated CpGs at critical posi-
tions in the binding interface, and an absence of preexisting
regulatory activity within the assayed cell type. Despite the po-
tential for CTCF occupancy at tens of thousands of potentially
competent recognition elements genome-wide, reactivation
was restricted specifically to elements that displayed highly var-
iable CTCF occupancy when assayed across 40 diverse cell
types. Our results suggest that DNA methylation does not playrs
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Figure 1. Profiling of TF Binding in Stably Demethylated Cells
(A) Normalized ChIP-seq profiles of CTCF occupancy in colorectal cancer cells depleted for methylation (HCT116, wild-type; DKO, double knockout of DNMT1
and DNMT3B) shows reactivated sites at RPTOR locus present in DKO, but not HCT116.
(B) Identification of CTCF-binding sites across 40 cell types. To conservatively identify variable CTCF sites, peaks were required to overlap a 0.5%FDR hotspot in
at least one cell type, but presence of a 1% FDR hotspot was sufficient to establish activity in subsequent cell types. The majority of CTCF-binding sites varies
across cell types.
(C–F) CTCF sites in HCT116 and DKO were classified based on ChIP-seq peak presence/absence (+/) in HCT116; significant difference in occupancy upon
demethylation in DKO (+ or +++, increased occupancy at 1% FDR using DESeq); and peak presence/absence (n.c., not considered) in other 39 cell types.
(C) Summary of classification scheme is shown. (D) Global view shows occupancy in HCT116 and DKO cells. Aminority of sites exhibited increased occupancy in
DKO (red and magenta sites above diagonal). (E) Quantitative comparison shows mean occupancy at each class of sites in HCT116, DKO, or other cell types
(measured as 90th percentile occupancy across 39 other cell types per site). Error bars represent SD. (F) Averagemethylation across 9,208 CTCF sites in HCT116
is shown. Reactivated sites are characterized by high preexisting methylation and unoccupied sites exhibit both unmethylated and unmethylated populations.
Downregulated sites (n = 5 with methylation data) are not shown. Horizontal bars represent mean.a significant primary role in repressing CTCF occupancy, but
rather serves amore specialized function targeted at labile occu-
pancy sites.
RESULTS
Most CTCF Binding Is Unaltered by Genomic Abrogation
of DNA Methylation
To comprehensively assess the degree of CTCF cell-type-spe-
cific occupancy, we performed dense profiling of the normal
CTCF occupancy landscape across 40 cell types in replicate
(Tables S1 and S2). We identified an average of 61,944 CTCF
sites in each cell type (range, 38,703–75,854) and a total of
107,295 CTCF sites across all cell types, which increased theCellpreviously documented CTCF-binding landscape (Wang et al.,
2012) by nearly 40% (Table S3). These data confirm that the
CTCF-binding landscape comprises a core minority of constitu-
tive sites (n = 19,023), but that the majority of its binding is cell
type specific (Figure 1; Figure S1A).
Partial disruption of the DNA methyltransferases DNMT1 and
DNMT3B in colorectal carcinoma cells (HCT116) through gene
targeting stably reduces global DNA methylation by 83%–95%
(Akalin et al., 2012; Rhee et al., 2002) and results in genome-
wide changes in gene expression and chromatin structure
(Lay et al., 2015; Pandiyan et al., 2013; Reddington et al.,
2013). However, the extent to which the observed alterations in
chromatin structure and gene expression are directly caused
by demethylation of specific sites versus secondary effectsReports 12, 1184–1195, August 18, 2015 ª2015 The Authors 1185
is undetermined. To determine the degree to which CTCF
occupancy was actively inhibited by DNA methylation, we per-
formed chromatin immunoprecipitation sequencing (ChIP-seq)
on HCT116 cells harboring homozygous knockouts of the major
DNAmethyltransferases DNMT1 andDNMT3B. Figure 1A shows
the results of multiple replicates of CTCF ChIP-seq in double
knockout (DKO) HCT116 cells in comparison with wild-type
HCT116 cells. To gauge precisely the alteration to CTCF binding
in the context of reduced genomic methylation, we partitioned
CTCF sites along two axes as follows: (1) significant differences
in occupancy (false discovery rate [FDR] 1%) between wild-type
HCT116 and DKO cells, and (2) whether or not each site was
occupied in wild-type HCT116 cells (Figure 1C; Experimental
Procedures). CTCF-binding sites from the 39 other cell types
that were not occupied either in HCT116 or DKO cells (unoccu-
pied) are shown for comparison. This analysis revealed that the
majority of sites in DKO cells were preexisting in wild-type
HCT116 cells and showed unchanged CTCF occupancy (by
sequencing read density) in DKO cells (Figure 1D). This sug-
gested that DNMT knockout had at best a minor effect on global
CTCF occupancy patterns.
To confirm a global lack of activation of CTCF occupancy
upon DNMT ablation, we quantified CTCF occupancy at
176,630 stringent matches genome-wide for the CTCF-binding
motif (Kim et al., 2007) that were completely null for CTCF occu-
pancy (i.e., did not exhibit CTCF occupancy in vivo in any cell
type with intact DNMTs; Figure 1E; Figures S1B–S1D; Experi-
mental Procedures). These elements showed complete lack
of occupancy, similar to that of a set of random sequences
without the CTCF recognition sequence. We thus concluded
that the CTCF-binding landscape is not significantly influenced
by a drastic reduction in genomic methylation.
Reactivation at a Limited Set of Methylation-Sensitive
Sites
Although the vast majority of preexisting CTCF occupancy sites,
as well as the vast majority of unoccupied CTCF recognition
sites, were unaffected by the reduction of DNA methylation, we
noticed that a small compartment of CTCF sites (n = 4,204)
showed significant (FDR 1%) methylation sensitivity. These
elements comprised 158 CTCF sites with reduced CTCF occu-
pancy (downregulated sites); 809 sites with increased CTCF oc-
cupancy (upregulated sites); and 3,237 sites found in DKO cells,
but not wild-type HCT116 cells (reactivated sites). Reactivated
elements were strongly occupied, showing similar occupancy
in DKO cells to preexisting sites in either cell type (Figure 1E),
suggesting that occupancy at a minority of CTCF sites is
uniquely susceptible to methylation.
To test whether binding at reactivated elements relied directly
on DNA methyltransferase function, we profiled CTCF occu-
pancy in single knockouts of DNMT1 and DNMT3B. In contrast
to DKO cells, each single knockout line is known to exhibit little
difference in global DNA methylation (Rhee et al., 2002).
Congruent with this, perturbation of single DNMT knockouts
did not show significant changes in CTCF occupancy (Figures
S1E and S1F). We thus conclude that novel CTCF occupancy
at a limited subset of CTCF recognition elements is a direct
consequence of the abrogation of methylation.1186 Cell Reports 12, 1184–1195, August 18, 2015 ª2015 The AuthoTo link reactivation at these elements to relief of methylation-
dependent repression, we examined methylation levels in
HCT116 cells (Varley et al., 2013) at a subset of CTCF sites.
Occupied sites demonstrated low methylation and unbound
sites showed high methylation (Figure 1F; Table S4), consistent
with older observations (Lister et al., 2009; Thurman et al.,
2012; Wang et al., 2012). Although reactivation occurred almost
exclusively (96%) at methylated sites, only 50% of methylated
sites were reactivated. Similarly, 90% of unbound CTCF ele-
ments were methylated but exhibited virtually no reactivation.
Given the low global level of remaining methylation in DKO cells
(Akalin et al., 2012; Rhee et al., 2002), it is unlikely the lack of
reactivation could have resulted from localized persistence of
methylation at unoccupied sites. Nevertheless, we verified using
published Methyl-Cap profiling of HCT116 and DKO cells (Sim-
mer et al., 2012) that both reactivated and unoccupied sites
showed essentially complete depletion of methylation in DKO
cells (Figure S1G). Thus, while methylation is not the sole barrier
to in vivo occupancy at themajority of sites genome-wide, loss of
DNAmethylation clearly potentiates CTCF binding at a subset of
recognition sites.
Reactivation Occurs at In Vivo-Verified Sites
We queried whether reactivated elements represented activa-
tion of CTCF sites with documented capacity for occupancy
in some cell type versus de novo activation of novel occupancy
sites. Strikingly, 91%of sites found in DKO cells, but not HCT116
cells, also were detected in at least one other cell type, suggest-
ing reactivation occurs at a subset of methylation-sensitive sites
with an intrinsic capacity for in vivo CTCF occupancy (Figure 2A).
Notably, 40,771 potentially reactivatable sites (i.e., found in other
cell types, but not HCT116) were not affected, suggesting that
methylation-sensitive sites are distinguished from inert CTCF
recognition sequence matches by specific characteristics.
Preferential Reactivation at CTCF Sites Silenced in
Transformed Cells
We next computed the frequency of CTCF occupancy at various
classes of CTCF recognition sites. We observed that binding at
both upregulated and reactivated sites appeared to be highly
variable across cell types (Figure 2B). Methylation-sensitive
occupancy was observed frequently at two classes of sites as
follows: (1) those found in almost all cell types (excluding
HCT116), and (2) sites found exclusively in malignancy-derived
or immortalized cell lines (Figure 2C). We observed CpG is-
land-associated hypermethylation in immortal, but not normal,
lines (Figure 2D), overlapping a subset of methylation-associated
cell-type-selective CTCF sites (Wang et al., 2012). This finding is
consistent with the regulation of several tumor suppressors and
oncogenes by methylation-dependent CTCF sites (Butcher
et al., 2004; Da´valos-Salas et al., 2011; Soto-Reyes and Recil-
las-Targa, 2010; Witcher and Emerson, 2009). Overall, the vast
majority (93%) of reactivated CTCF sites had at least one CpG
within the 44-bp region of protein-DNA interaction (compared
with only 54% of unoccupied sites), with reactivated sites
more frequently harboring CpGswithin the recognition sequence
(Figure 2E). Likewise, whereas 29% of the reactivated sites were
in CpG islands, this was the case for only 10% of unoccupiedrs
se
qu
en
ce
 m
at
ch
es
pr
ee
xi
st
in
g
u
pr
eg
ul
at
ed
u
n
o
cc
u
pi
ed
re
a
ct
iva
te
d
A
D E
Im
m
or
ta
l
N
or
m
al
CTCF binding in DKO
C
CTCF site in 39
other cell types
(n=3,237)
Reactivated sites
Site unique to DKO
(n=704) constitutivesites
cell-type
specific
B
T
G
A
CC
C
T
G
A
A
G
C
G
A
T
C
C
T
G
AG
TA
G
C
A
T
G
A
G
C
A
T
G
G
T
A
C
CTA
G
T
A
G
C
A
G
T
C
0 CpG: CCACCAGAGTGCAC
1 CpG: CCACCAGAGTGCGC
CpG content
core recognition sequence
(full length=44 bp)
BJ
NHDF Neo
AG10803
AG09319
AG09309
AG04450
AG04449
HCPEpiC
HCM
RPTEC
HRE
HRPEpiC
SAEC
HEEpiC
HMEC
Sk-N-Sh_RA
BE2_C
GM06990
GM12878
HepG2
K562
HEK293
A549
Caco-2
MCF-7
HeLa-S3
HCT116
0.2 0.60.4 0.8
Avg. Methylation
Pr
op
.
 
o
f s
ite
s 
va
ria
bl
e 
ac
ro
ss
 c
el
l t
yp
es
0.0
0.2
0.4
0.6
0.8
1.0
pre
exi
stin
g
up
reg
ula
ted
re
ac
tiva
ted
un
oc
cu
pie
d
Prop. of cell types w/ CTCF peak
Pr
op
.
 
o
f s
ite
s 
re
ac
tiv
a
te
d
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.0 0.2 0.4 0.6 0.8 1.0
Normal cells (n=25)
Immortal lines (n=14)
Overall reactivation
Pr
op
.
 
si
te
s 
w
/ C
pG
 in
 re
co
gn
itio
n 
se
q.
0.0
0.2
0.4
0.6
0.8
1.0
pre
exi
stin
g
up
reg
ula
ted
re
ac
tiva
ted
un
oc
cu
pie
d
Figure 2. Reactivation of Predetermined
Lineage-Specific Sites
(A) Overlap of reactivated sites with CTCF-binding
sites known from other cell types. The minority of
sites unique to DKO represents novel binding sites
not known from our catalog of 40 cell types.
(B) Overlap of methylation sensitivity with sites
variable across cell types (y axis) is shown.
(C) Reactivation frequency (y axis, computed as
the number of reactivated sites divided by the
number of reactivated and reactivated sites) at
sites found in all normal cell types but silenced in
HCT116 (solid line, right), as well as immortal-only
sites not found in normal lines (solid line, left), is
shown.
(D) Methylation at CTCF sites across 29 cell types
(Varley et al., 2013). Note increased methylation in
immortalized cell lines in reactivated and upregu-
lated sites (boxes).
(E) Proportion of sites with a CpG in their recog-
nition sequence. Note the increased frequency in
upregulated and reactivated sites.sites. We thus conclude that many of the methylation alterations
observed at high-CpG regions in the context of malignant trans-
formation (Varley et al., 2013; Wang et al., 2012) are accompa-
nied by disrupted CTCF occupancy at a highly specific set of
labile sites.
Cooperative Binding at CTCF Sites ImpedesMethylation
Sensitivity
Despite the very large potential genomic occupancy space
defined by stringent matches to the CTCF recognition sequence,
reactivation is not observed outside of experimentally verified
binding sites (by ChIP-seq). We thus asked what features
distinguish reactivated CTCF sites from potential recognition
sites that were not responsive to demethylation. Chromatin
context and DNA accessibility are obvious candidate factors in
discriminating such sites (John et al., 2011). To probe the role
of DNA accessibility in potentiating CTCF occupancy upon
demethylation, we profiled HCT116 and DKO cells using DNase
sequencing (DNase-seq). We also quantified chromatin modifi-
cation state using ChIP-seq for trimethylation of histone 3 lysine
4 (H3K4me3) and acetylation of histone 3 lysine 27 (H3K27ac)Cell Reports 12, 1184–1195,(Figure 3A; Table S5). At the vast majority
of sites, we found CTCF occupancy to be
tightly associated with the DHSs; how-
ever, only 17% of reactivated sites over-
lapped a DHS in HCT116 cells (Figure 3B;
Table S6). We thus concluded that
de novo recruitment of CTCF does not
require targeting to accessible chromatin
sites prior to demethylation.
Indeed, reactivated CTCF sites over-
lapped DHSs in HCT116 cells signifi-
cantly less frequently than unoccupied
sites (Figure 3B; Figure S2A). Further-
more, the association of reactivation
with CpG content was almost entirelyspecific to sites without preexisting accessible chromatin
(Figure 3C). The presence of H3K4me3 was similarly antago-
nistic to reactivation (Figure S2B), and the presence of both
DNase I hypersensitivity and H3K4me3 was associated with an
absence of methylation specifically at unoccupied sites, despite
a lack of CTCF occupancy (Figure 1F; Figure S2C). Finally, unoc-
cupied sites were enriched for the occupancy of 17 TFs (Fig-
ure S2D) studied by the ENCODE project (ENCODE Project
Consortium, 2012). Thus, pre-established cell-type-specific
binding by other TFs actively impedes CTCF recruitment,
regardless of DNA methylation.
Chromatin Dynamics at Reactivated CTCF Sites
Given that the removal ofDNAmethylationmight indirectly enable
CTCF occupancy subsequent to a broader relaxation of chro-
matin state (Ooi et al., 2007; Thomson et al., 2010), we then asked
whether relaxed chromatin structure required the reactivation of
CTCF binding. DNase I accessibility increased in tandem with
CTCF occupancy at reactivated and upregulated sites and
decreased at downregulated sites, but only a subset of CTCF
reactivation was accompanied by concomitant reactivation ofAugust 18, 2015 ª2015 The Authors 1187
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Figure 3. Chromatin Dynamics at Reactivated CTCF Sites
(A) Profiling of CTCF, DNase I, and H3K4me3 in HCT116 and DKO cells is shown.
(B) Proportion of CTCF sites overlapping DNase I-hypersensitive sites (DHSs). Although preexisting CTCF sites are stereotypically hypersensitive to DNase I
cleavage, reactivation upon demethylation occurs at sites inaccessible in HCT116.
(C) Reactivation frequency parallels local CpG content (solid blue line), while the presence of a preexisting DHS is associated with a near-total lack of reactivation
regardless of CpG content (dashed green line).
(D and E) Increased CpG content (x axis) is strongly associated with reactivation of H3K4me3 (D), but not DNase I (E). Shown are sites without H3K4me3 peak (D)
or DHS and CTCF peak (E) in HCT116. Note strong reactivation of H3K4me3 at unoccupied CTCF sites in contrast to a lack of increase in DNase I at these sites.
(F) While H3K4me3 increases irrespective of CTCF reactivation, DNase I at CTCF sites coincides frequently with reactivation of CTCF occupancy.H3K4me3 (Figures S2E–S2I). In fact, H3K4me3 reactivation
occurred regardless of CTCF recruitment and depended strongly
upon CpG content (Figure 3D), consistent with the recognition
of unmethylated CpG islands by Cfp1 (part of the Set1 methyl-
transferase complex) (Thomson et al., 2010). In contrast, the rela-
tionship between DNase I reactivation and CpG content was
conditional on CTCF reactivation (Figures 3E and 3F). Thus,
we conclude that, while H3K4me3 is deposited in unmethy-
lated regions of high CpG content regardless of CTCF occu-
pancy, DNase I accessibility specifically marks regulatory factor
occupancy.
We investigated whether other TFs might exhibit global sensi-
tivity to DNA methylation by examining genome-wide profiles of
H3K4me3, H3K27ac, and DNase I in HCT116 and DKO cells. The1188 Cell Reports 12, 1184–1195, August 18, 2015 ª2015 The Authovast majority of H3K4me3 (84%) and H3K27ac (88%) peaks
in DKO cells overlapped with DHSs. DKO cells manifested an
expanded accessible chromatin landscape, comprising a 61%
increase in the number of DHSs (Figures S2J–S2L). This repre-
sents a surprisingly small increase given the expanse of poten-
tially reactivated DHSs known from other cell types. Detailed
statistical analysis revealed 12,279 DHSs with differential acces-
sibility, 96% of which were not present in HCT116 cells. Fully
70% of these DHSs were present in a survey of 124 cell types
(Maurano et al., 2012a), confirming preferential reactivation of
silence sites from other lineages. This set of reactivated DHSs
included a majority of the reactivated CTCF sites (between
48% and 77%, depending on FDR cutoff); but, despite the large
number of genomic CTCF occupancy sites and its pivotal role atrs
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Figure 4. CpGs at Key Positions in the
Protein-DNA Binding Interface Drive
Reactivation
(A) Linear regression coefficients (y axis) esti-
mating the contribution of the presence of a
CpG dinucleotide in the CTCF recognition
sequence (consensus binding motif shown at
top) to reactivation upon abrogation of methyl-
ation. Window is defined as the 44-bp extent of
protein-DNA contact demarcated by DNase I
footprint. *Position is significant in regression
(p < 0.05, Bonferroni corrected).
(B) Methylation-sensitive positions identified
in vitro through electrophoretic mobility shift assay
(EMSA) are shown (Renda et al., 2007).
(C) Association of CpG presence with methylation-
associated cell-type variability across 19 cell types
is shown (Wang et al., 2012).
(D) SNPs associated with significant alteration in
occupancy across individuals are shown (from
Figure 3B; Maurano et al., 2012b).imprinted loci, fully 90% of reactivated DHSs were not CTCF
sites (Figure S2M).
MethylationModulates the CTCF-DNA Binding Interface
at Labile Sites
To examine whether the association of CpG content with reacti-
vation (Figure 3C) localized to specific positions in the protein-
DNA interface (Renda et al., 2007; Wang et al., 2012; Wiench
et al., 2011), we used a regression model to quantify the contri-
butions of CpG dinucleotides at each position in the recognition
sequence. We found that critical CpGs were concentrated in
the core binding region, consistent with in vitro sensitivity to
methylation (Renda et al., 2007), the positions of CpGs at sites
of methylation-associated cell-type-selective binding (Wang
et al., 2012), and sensitivity to single-nucleotide variants (Maur-
ano et al., 2012b; Figure 4). Reactivation was associated with
the strength of the match to the CTCF consensus sequence,
also consistent with a direct effect on CTCF binding (Figure S3A).
By classifying CTCF-binding sites by sequence similarity into
three known binding modes (Bowers et al., 2009; Filippova
et al., 1996; Nakahashi et al., 2013; Ohlsson et al., 2001; Rhee
and Pugh, 2011), including engagement of zinc fingers 3–7
(core sites) and additional specific interactions by zinc fingers
8–10 (upstream and extended spacing sites), we found that
core sites were reactivated 42% more frequently than upstream
sites (Figure S3B), supporting speculation that different modes
of engagement of its 11 zinc fingers may confer functional selec-
tivity (Ohlsson et al., 2010).Cell Reports 12, 1184–1195,Cell-Type-Specific Reactivation
Highlights Methylation-
Independent Repression
We next asked whether reactivation of
methylation-sensitive CTCF sites could
be reproduced in an independent sys-
tem combining both a different cellular
context and a different methodology for
depleting DNA methylation. Chemical in-hibition of DNA methyltransferases by 5-aza-20-deoxycytidine
(5-aza-CdR) transiently reduces global methylation levels and
has been reported to reactivate TF binding and increase gene
expression (Hagemann et al., 2011; Komashko and Farnham,
2010; Qiu et al., 2010; Rodriguez et al., 2010; Witcher and Emer-
son, 2009). We thus profiled the effect of 5-aza-CdR treatment
on CTCF binding in K562 cells, which have an erythroid pheno-
type that differs markedly from the colonic epithelial phenotype
of HCT116 cells (Thurman et al., 2012). In K562 cells, 5-aza-
CdR treatment resulted in weaker reactivation than in DKO cells,
including 767 reactivated, 191 upregulated, and 4 downregu-
lated sites (Figures 5A and 5B).We used a targeted sodium bisul-
fite approach to confirm a more limited reduction of methylation
than in DKO cells (Experimental Procedures; Table S7; Fig-
ure S4), consistent with previous reports (Hagemann et al.,
2011; Pandiyan et al., 2013; Rhee et al., 2002). Reactivation
was again largely specific to sites of preexisting methylation:
79% of reactivated sites were methylated in K562 cells. How-
ever, we found a complex relationship between methylation
and occupancy (Figure S4D) that suggested widespread sec-
ondary effects, consistent with previous observations that 20%
of variable CTCF sites are unmethylated in all cell types (Wang
et al., 2012) and that most 5-aza-CdR-induced alterations
in gene expression or chromatin structure occur at previously
unmethylated sites (Komashko and Farnham, 2010).
Despite the lesser extent of reactivation with 5-aza-CdR in
K562 cells, we found that fully 69% of sites reactivated with
5-aza-CdR overlapped sites that were concordantly reactivatedAugust 18, 2015 ª2015 The Authors 1189
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Figure 5. Cell-Type-Specific Reactiva-
tion Highlights Methylation-Independent
Repression
(A) CTCF ChIP-seq at NTRK3 locus shows
reactivated and preexisting sites in a mock- and
5-aza-CdR-treated K562 cells.
(B) Quantitative comparison of CTCF occupancy
in mock and treated cells shows limited but
reproducible reactivation (FDR 1%). Sites were
classified (labels) based on the presence of peak in
mock-treated K562 and significant differential
occupancy in treated cells.
(C) Overlap with reactivation in DKO at 46,726
potential sites not occupied in both K562 and
HCT116; FDR 5% hotspots. The majority of
5-aza-CdR-reactivated sites are concordantly re-
activated in DKO.
(D) Sites reactivated in K562 (solid line) are
more likely to be reactivated in DKO (y axis) than
unoccupied sites (dashed line), regardless of CpG
content.
(E) Reduced preexistingmethylation (y axis) in both
K562 (left) and HCT116 (right) distinguishes sites
reactivated specifically by genetic or chemical
means, suggesting that non-concordant sites are
attributable to methylation-independent silencing.
p values by Wilcoxon signed-rank test. Error bars
represent SD.
(F) Model of cell-type-specific repression of
TF occupancy. Concordant reactivation implies
methylation-dependent silencing across cell types,
while discordant reactivation implies methylation-
independent silencing in the unoccupied cell type.in HCT116/DKO cells (Figure 5C). Sites reactivated in both cell
types demonstrated CpG-dependent reactivation (Figure 5D)
and high preexistingmethylation in both K562 and HCT116 cells,
further supporting the existence of a predetermined class of
methylation-dependent sites. Sites reactivated only in a single
cell type demonstrated significantly less methylation (Figure 5E),
revealing the presence of methylation-independent silencing
mechanisms in the unoccupied cell type (Figure 5F).
Sequence Recognition of Labile Methylation-Sensitive
Sites
We examined the relative predictive power of genomic charac-
teristics to recognize the minority of sites that were reactivated1190 Cell Reports 12, 1184–1195, August 18, 2015 ª2015 The Authors(Figures 6A and 6B). The single most
predictive factor was the number of
CpGs at critical positions in the recogni-
tion sequence. The number of CpGs in
the flanking regions was almost as pre-
dictive, probably due to the regionally
high CpG density of CTCF sites. The sec-
ond most predictive factor was lack of
chromatin accessibility in HCT116 cells.
As many of the features surveyed are
not independent, we used a logistic
regression model to assess their com-
bined predictive power (Experimental
Procedures). A model considering justchromatin accessibility and number of CpGs was more predic-
tive (area under the curve [AUC] of 0.82) than either factor alone
and almost as predictive as the full model (AUC 0.84), indicating
that the remaining factors provide only minor additional discrim-
inative power. Although we observed increased reactivation at
exons, the increased G+C content of protein-coding sequence
is presumably responsible for a markedly increased reactivation
frequency relative to other genomic sequence (Figure S5A),
which suggests an altered regime of methylation-regulatory fac-
tor interaction at these sites (Stergachis et al., 2013). At sites for
whichmethylation data were available, the degree ofmethylation
alone had strong predictive power; but, this predictive power
was largely redundant when DNase I accessibility and number
AC
B Figure 6. Recognition of Labile Methyl-
ation-Sensitive Sites
(A and B) Predictive power of genomic features
to distinguish reactivated from unoccupied sites,
illustrated by receiver-operator curves (ROCs).
Area under the curve (AUC) summarizes overall
predictive power. (A) Full ROCs highlight for
models considering (1) just CpGs at specific po-
sitions, (2) DNase I in HCT116, (3) both together, or
(4) all features together (Experimental Procedures).
Dashed gray line indicates a random predictor and
has an AUC of 0.5. A perfect predictor would be
plotted as a right angle and have an AUC of 1.
(B) Detailed predictive power (y axis) of selected
genomic features is shown. Models include
methylation (bracketed) measured only at sites
with RRBS data. Green bars indicate linear models
combining multiple factors. Other TF occupancy
refers to the sum of HCT116 ENCODE TF ChIP-
seq track densities.
(C) Model shows methylation sensitivity at labile
CTCF sites.of CpGs additionally were considered, suggesting that the latter
features primarily provide indication of methylation status (Fig-
ure S2C). Thus, just as sequence features are associated with
CTCF-binding sites conserved across six mammals (Schmidt
et al., 2012) and SNPs affecting CTCF occupancy (Ding et al.,
2014; Maurano et al., 2012b), a simple sequence model consid-
ering CpG content can reliably distinguish the minority of reacti-
vated sites (Figure 6C).
DISCUSSION
The potential for DNA methylation to shape TF-binding land-
scapes, with consequent effects on gene expression patterns,
has been invoked frequently but not studied systematically.
Although methylation-sensitive CTCF binding to the Igf2/H19-
imprinted locus represents the paradigmatic model of the
relationship of DNA methylation to gene regulation (Bell and
Felsenfeld, 2000; Hark et al., 2000), the results reported herein
reveal a limited and highly specific response of CTCF occu-
pancy to DNA methylation depletion. The observed effects
are consistent across cellular contexts and under both transient
and stable inhibition of DNA methyltransferases, suggesting
their generality. Given the global lack of correlation between
methylation changes and altered binding, these results place
a limit on the extent of CTCF-mediated coupling between
DNA methylation and genome organization, cautioning againstCell Reports 12, 1184–1195,a facile interpretation of alterations of
DNA methylation in oncogenesis.
Our results contrast with the well-
established relationship between DNA
methylation and reduced CTCF binding
(Bell and Felsenfeld, 2000; Wang et al.,
2012), and they qualify that this relation-
ship is only causal at a small subset of
sites in vivo. Yet although DNA methyl-
ation does not play a significant primaryrole in repressing TF occupancy, the presence of methylation
sensitivity at labile sites suggests that it may nevertheless modu-
late their epigenetic stability. This interpretation is consistent
with a model whereby DNA methylation is passively deposited
in the abrogation of TF binding and acts as a cooperative switch
to prevent the return of binding after a reprogramming event
(Stadler et al., 2011; Wang et al., 2012).
Strikingly, reactivation is strictly limited to in vivo CTCF sites
from other cell types, highlighting that these silent sites are
globally distinguished from other matches to the CTCF recogni-
tion sequence. Although CTCF preferentially recognizes a DNA
sequence with higher information content than most other
human TFs—fully 24% of CTCF recognition sequences are
within 500 bp of an in vivo CTCF-binding site—our work confirms
that its recognition sequence alone is insufficient for recruitment
even at unmethylated sites. But it remains unclear how bona fide
CTCF sites are distinguished from inert sequence matches:
these silent sites are not marked by DNase I accessibility and,
in fact, reactivation is less frequent in the presence of cofactors.
However, approximately half of reactivated and unoccupied
sites are accessible to DNase I in human embryonic stem cells,
compared to only 11% of sequence matches, suggesting that
the marking of bona fide CTCF sites occurs early in develop-
ment. It is possible that topological considerations (Rao et al.,
2014) or cooperative binding with as yet undetermined factors
play a role in the determination of its in vivo binding sites.August 18, 2015 ª2015 The Authors 1191
Despite the secondary role of DNA methylation at most CTCF
sites, the small set of reproducibly reactivated sites is distin-
guished by solitary CTCF binding and clear sequence charac-
teristics including the presence of CpGs at key positions in the
binding interface. The strongest factor distinguishing reactivated
sites is the presence of CpG dinucleotides at key positions of the
protein-DNA recognition interface, consistent with previous
results showing that the methylation is specifically depleted at
sites of TF occupancy marked by DNase I footprints (Groudine
and Conkin, 1985; Neph et al., 2012b; Stadler et al., 2011).
This selective effect of sequence features is reminiscent of
single nucleotide genetic variants within the CTCF recognition
sequence (Maurano et al., 2012b), and in turn suggests that
TF-DNA recognition interfaces are intrinsically buffered against
both genetic and epigenetic perturbations. The conferral of
methylation-sensitive binding by the presence of CpG dinucleo-
tides at key positions in the recognition interface at elements
showing labile occupancy across cell types provides a poten-
tially unifying link among sequence features, DNA methylation,
and epigenetic regulatory state (Gaidatzis et al., 2014; Neph
et al., 2012b).
EXPERIMENTAL PROCEDURES
Cell Culture and ChIP-Seq/DNaseI-Seq
HCT116 and DKO cells have been described previously (Rhee et al., 2002).
Cells were cultured in appropriate medium and maintained in a humidified
incubator at 37C in the presence of 5% CO2. (Table S1). K562 cells were
treated with 5-aza-CdR (decitabine; Sigma, A3656) dissolved in DMSO to
10 mM. The drug was administered at 1 mM daily for 3 days. Control K562
cells were mock-treated with DMSO. Conditions for other cell types were as
described in Table S1.
Chromatin immunoprecipitations were performed as described previously
for CTCF (Wang et al., 2012) and H3K4me3 and H3K27ac (Thurman et al.,
2012). Briefly, cells were crosslinked for 10 min in 1% formaldehyde and
quenched in 125 mM glycine. Chromatin was sheared by Bioruptor (Diage-
node) and incubated with antibody conjugated to Dynabeads (M-280, Invitro-
gen). After reversing crosslinks, immunoprecipitated DNA was purified by
phenol-chloroform-isoamyl alcohol extraction and ethanol precipitation.
DNase was performed as described previously (John et al., 2011; Thurman
et al., 2012), whereby small (<500-bp) fragments are isolated from lysed nuclei
following DNase treatment. Libraries generated from immunoprecipitated
or DNase-treated DNA were sequenced on an Illumina Genome Analyzer IIx
or HiSeq 2000 by the High-Throughput Genomics Center (University of Wash-
ington) according to a standard protocol. Most experiments were performed
on two independent biological replicates (Tables S2 and S5).
Data Processing
ChIP-seqandDNasedataweremapped to the humangenome (GRCh37/hg19)
using bowtie (Langmead et al., 2009) with the options ‘‘bowtie -n 2 -m 1 -e 70–
best’’ allowing up to two mismatches. Reads mapping to multiple locations
were then excluded, and reads with identical 50 ends and strand were pre-
sumed to be PCR duplicates and were excluded using PicardMarkDuplicates.
Smoothed density tracks were generated using bedmap (https://bedops.
readthedocs.org/) to count the number of reads overlapping a sliding 150-bp
window, with a resolution of 20 bp (Neph et al., 2012a). Density tracks
for display were normalized for sequencing depth by a global linear scaling to
10 million reads.
CTCF data from 39 cell types were processed as described previously
(Wang et al., 2012). Briefly, a master peak list (Table S3) was established
from ENCODE project 2% irreproducible discovery rate (IDR)-processed
SPP peak calls (Kharchenko et al., 2008; Li et al., 2011; ftp://ftp.ebi.ac.uk/
pub/databases/ensembl/encode/supplementary/integration_data_jan2011/1192 Cell Reports 12, 1184–1195, August 18, 2015 ª2015 The AuthobyDataType/peaks/june2012/spp/optimal/), with locations adjusted to
center on matches to the nearest CTCF motif (p < 104, FIMO) if the motif
was within 50 bp. An IDR-thresholded peak was additionally required to over-
lap a 0.5% FDR hotspot in both replicates. To conservatively identify variable
sites, peak presence in a given cell type was established by the presence of a
1% FDR hotspot (John et al., 2011; also http://www.uwencode.org/proj/
hotspot/) in any replicate. Peaks only found in DKO and/or 5-aza-CdR-treated
K562 cells were not included in total peak counts. We identified possible
further CTCF-binding sequences using the program FIMO (p < 105), as well
as random sequences without a CTCF-binding sequence (p > 104). Both
sets were required to be further than 500 bp from any known in vivo CTCF
site, to consist of base pairs 90% of which are uniquely mappable by 36-bp
reads, and not to be on the ENCODE blacklist (ENCODE Project Consortium,
2012). We identified DHSs by the presence of a hotspot (FDR 1%) in any
HCT116 replicate or a hotspot (FDR 0.5%) in DKO cells; novel sites in DKO
cells were included in the analysis if they overlapped no unthresholded hotspot
in any HCT116 replicate. H3K4me3 and H3K27ac regions were called using
hotspot.
At both CTCF sites and DHSs separately, we measured CTCF occupancy or
DNase I accessibility by the number of reads overlapping the 150-bp region
and H3K4me3 and H3K27ac density by reads overlapping the 2150-bp region.
We then used the package DESeq (Anders and Huber, 2010) to identify signif-
icant differences. CTCF ChIP-seq peaks or DHSs discordant between the two
previously published replicates and the new replicate for HCT116 (FDR 10%)
were removed. Pairwise differences were called between samples for
each ChIP-seq and DNase I dataset using estimateDispersions (method =
pooled, sharingMode = maximum, and fitType = local) and nbinomTest. After
observing a near-complete lack of reactivation at sequence matches and
random sites (less than ten sites), we subsequently excluded these sites and
recomputed pairwise differences. We applied the Benjamini-Hochberg proce-
dure to control for multiple testing. To obtain normalized data at all sites, we
used estimateDispersions as before but with fitType = parametric, and then
we applied a variance-stabilizing transformation and averaged the occupancy
of all replicates. These values were scaled to [0, 10] by subtracting the global
minimum and dividing by the global maximum * 10.
We obtained the location of CTCF sites relative to genes using RefSeq and
relative to CpG islands and repetitive regions in RepeatMasker from the Uni-
versity of California, Santa Cruz (UCSC) Genome Browser.
Classification of CTCF Motif Models
CTCF binds in a multivalent fashion, whereby three modes of binding are
distinguished by the presence and position of an upstream motif (Nakahashi
et al., 2013). At each site we chose the bestmatching (by FIMOp value) of three
motif models.
Per-nt Regression Model
We used the lm() function in R to perform a logistic regression considering
all preexisting, upregulated, unoccupied, and reactivated CTCF sites with a
recognizable motif as follows:
reactivation  c+ x22 +.+ x21 + upstream+ ðCpGs in flanking regionÞ;
where upstream represents an indicator variable for the presence of either up-
stream motif. Multiple testing correction was performed using the Bonferroni
method.
ROC and PR curves were computed using the R package ROCR. Logistic
models for multiple factors were constructed using the lm() function in R.
Monitoring Methylation
Purified DNA from mock- and 5-aza-CdR-treated K562 cells was fragmented
following the Agilent SureSelect Methyl-Seq protocol with slight modifications
(Table S7). DNA (4 mg) from each of the samples was fragmented in a Covaris
S2 under the following conditions: 10% duty cycle at intensity 5 for 60 s, with
200 cycles per burst for 6 cycles with mode set to sweeping. The 250-bp
fragmented DNA was then end-repaired and adenylated, followed by ligation
to adapters synthesized with 50-methylcytosine in place of of cytosine. Thers
adaptor-ligated library was purified using AMPure XP beads (BeckmanCoulter
Genomics). Next, 500 ng of each library was hybridized to Agilent SureSelect
Methyl-Seq biotinylated RNA baits (84 Mbp) for 24 hr at 65C. The biotinylated
probe/target hybrids were captured on Dynal MyOne Streptavidin T1 (Invitro-
gen), washed, eluted, and desalted following purification on a MinElute PCR
column (QIAGEN), as described in the SureSelect protocol.
Bisulfite conversion of the purified captured library was performed using the
EZ DNA Methylation Gold Kit (Zymo Research) as per the manufacturer’s
instructions. The bisulfite-converted captured library was amplified by PCR
with a minimal amount of PCR cycles, then purified using AMPure XP beads
and quantified by Qubit dsDNA assay (Invitrogen) following the SureSelect
protocol.
Samples were diluted to a working concentration of 10 nm. Cluster genera-
tion was performed for each sample and loaded onto a single lane of an
Illumina HiSeq flowcell. Single-end sequencing was performed for 36 cycles
according to the manufacturer’s instructions.
Capture bisulfite reads were mapped to the human genome (hg19) using
Bismark (Krueger and Andrews, 2011) and bowtie2 beta 6 (Langmead et al.,
2009) with the options ‘‘-n 1’’ and excluding duplicate reads and combining
reads from the top and bottom strands. Methylation was monitored at CpGs
with eight or more read coverage and averaged for all CpGs within the
150-bp window at each CTCF site. We obtained eight or more times coverage
in both samples for 658,010 CpGs.
Reduced representation bisulfite sequencing (RRBS) data for 29 cell types
are available from the UCSC Genome Browser (Varley et al., 2013), processed
as described previously (Wang et al., 2012).
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